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Abstract
Boronic Acids as Penicillinase Inhibitors
by
Juan F. Barquero
Advisor: Dr. Manfred Philipp.
β-lactamases are enzymes produced by bacteria resistant to antibiotics. A common feature on
beta lactam antibiotics is the beta-lactam ring. β-lactamases hydrolyze the β-lactam ring leaving
the antibiotic inoperative. The advent of bacteria that are resistant to β-lactams has impelled
researchers to find inhibitors for β-lactamases that mimic the lactam ring but do not get
hydrolyzed. One group of these new antibiotics is the aryl boronic acids. The main reason the
boronic acids have been chosen as potential drugs is their lack of toxicity and their easy
excretion in the urine. One of the most important structural features of these compounds is their
chemical and geometric fitness in the active site of β-lactamases. Boronic acids mimic the
tetrahedral intermediate formed in the half-acylation reaction that occurs during the hydrolysis of
the β-lactam ring. The major goal of the research presented here was to discover new aryl
boronic acids inhibitors of penicillinases from the class A β-lactamases. To accomplish this goal,
commercially available boronic acids that are manufactured for the Suzuki reaction were used.
These compounds included fluorinated, chlorinated, brominated, carboxylated, nitrophenylated,
pinacol-esterified and thiophene-carboxylated aryl boronic acid derivatives. Kinetic evaluations
of each class of compounds were performed under pseudo first-order enzymatic reaction
conditions and the inhibitory constants (Ki) were reported using nitrocefin as substrate for two
enzymes: the in-house expressed β-lactamase BlaC and the β-lactamase from Bacillus cereus
569/H9 (Calbiochem) identified as TEM-116. The structure-activity relationship (SAR) showed
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that the most potent inhibitors of BlaC β-lactamase were 2-carboxythiophene-5-boronic acid;
3,4,5-trifluorophenylboronic acid; 3-nitrophenytlboronic acid and 2,3,4,5tetrafluorophenylboronic acid, Ki values of 1.2, 175.7, 213.9 and 228.6 micromolar respectively.
In addition, SAR revealed that the most potent inhibitors for Bacillus cereus β-lactamase I were
2-carboxythiophen-5-boronic acid, 3-carboxyphenylboronic acid, 2-carboxythiophene-4-boronic
acid, and 3-carboxy-4-fluorophenylboronic acid having Ki values of 1.1, 19.4, 46.5, and 47.1
micromolar respectively. To gain further insight into the molecular interactions between each
class of inhibitors and their targeted enzymes docking experiments were performed using
Autodock Vina program combined with Sculpt from MDL and followed by the molecular
visualization of the protein-ligand complexes using Swiss-PdbViewer and DiscoveryStudio from
Accelerys. The results conclusively show that some selective classes of aryl boronic acids are
potent competitive inhibitors of BlaC and Bacillus cereus β-lactamase I and that they should be
further considered for advanced drug discovery and improvement of treatment against antibiotic
resistant bacteria. Furthermore, the discovery that 4,4’-DDT is an inhibitor of Mycobacterium
tuberculosis β-lactamase, combined with in silico studies, suggests that further elaboration of
this molecule may be one route to new inhibitors.
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1. Introduction
1.1. β-Lactamases: Structure-function relationship and target for drug discoveries
It has come to the attention of the scientific community, the authorities and the public that
infection by Mycobacterium tuberculosis is latent in approximately 2 billion people globally
(Flores et al., 2005); The incidence of tuberculosis has been increasing exponentially in the last
decade, and that no new specific drug against tuberculosis has been found; After AIDS, the
leading cause of mortality due to infection is tuberculosis, 2 to 3 million deaths per year on a
global scale (Andries et al, 2005). The widespread use and misuse of antibiotics globally has
aggravated the problem and has contributed to the emergence on new diseases and antibiotic
resistant pathogens (Essack, 2001). Resistance to antibiotics by pathogens has been influenced
by man in the last 60 years (Fisher et al., 2005). β-lactam antibiotics have been known since the
discovery of penicillin from Penicillium notatum by Alexander Fleming in 1927 (Deshpande et
al., 2004). However, it is claimed that even before Fleming, Lister and Sanderson at Oxford
utilized a fungal extract for localized wounds in 1911 (Deshpande et al., 2004). Soon after
penicillin’s clinical success, other antibiotics were developed such as streptomycin in 1943,
chloramphenicol in 1947, chlortetracycline in 1948, neomycin in 1949, erythromycin in 1952
(Deshpande et al., 2004), and isoniazid in the 1950’s. The first enzyme known to hydrolyze
penicillin was the AmpC β-lactamase of Escherichia coli (Jacoby, 2009). Today 470 βlactamases have been identified and classified into four groups from A to D (Verna et al., 2013).
The penicillins expanded to orally active penicillins, broad spectrum and enzymatically stable
penicillins, and then the cephalosporins of three generations, the monobactams, carbapenems, β-
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lactamase stable penicillins and cephalosporins, and β-lactamase inhibitors (Foye et al., 1995).
Commercially available penicillins are divided into groups (Foye et al., 1995):
•

Fermentation-derived penicillins: 6-aminopenicillin acid (6-APA), benzylpenincillin
(penicillin G), phenoxymethylpenicillin (penicillin V).

•

Penicillinase-resistant parenteral (administered by other channels than digestive track)
penicillin: Methicillin.

•

Penicillinase-resistant oral penicillins: Oxacillin, cloxacillin, dicloxacillin.

•

Penicillinase-sensitive, broad-spectrum, parenteral penicillin: Carbenicillin, carindacillin,
azlocillin, mezlocillin, ticarcillin, piperacillin, ampicillin, amoxicillin, and miscellaneus
becamicillin, mecillinam.

Commercially-available β-lactamase inhibitors approved by the Food and Drug Administration
(FDA) are: Sulbactam, tazobactam, clavulanate (Hugonnet and Blanchard, 2007), and cefepime
(Barlow and Hall, 2003).
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Figure 1: Core structure for clinically available β-lactams. (Foye, 1995). (Structures drawn in
IsisDraw).

3

Figure 2: FDA-approved commercially available β-lactamase inhibitors. (Hugonnet and
Blanchard, 2007, Barlow and Hall, 2003) (Structures drawn in IsisDraw)
β-lactamases are enzymes that hydrolyze the β-lactam ring, a common feature in antibiotics
(Figure 1. b), rendering them inoperative. β-lactamases are the main cause of resistance to the
attack of penicillin and the β-lactam in bacteria (Matagne et al., 1998). The growing numbers of
bacteria that are becoming antibiotic-resistant are of major concern (World Health Organization,
4

2007). Their great adaptability makes them diverse and difficult to eliminate (Fisher et al., 2005).
The enzyme that bacteria produce, β-lactamase, disables β-lactams before they reach their target.

N
O
Figure 3: Penicillin-G and a β-lactam ring. a) Penicillin-G potassium salt. (From Sigma
Aldrich.com website) (Lee, 2005). b) β-lactam ring. (Picture drawn in Isis Draw from MDL).
The cell wall
The cell wall in bacteria is a complex rigid structure, which function is to protect the cell from
lysing when the water pressure increases inside the cytoplasm and to protect it from the
environment. It is a macromolecular complex of peptidoglycan (also called murein).
The backbone of the peptidoglycan is formed by a disaccharide N-acetylglucosamine (NAG)
and N-acetylmuramic acid (NAM) linked by a β-1,4 glycosidic bonds, in rows of 10 to 65 sugars.
Adjacent rows are linked by polypeptides that may change in length, but always include
tetrapeptides (Tortora, 1998). Depending on the structure of the cell wall bacteria have been
classified as Gram-positive and Gram-negative bacteria. Gram-positive remain purple after
alcohol is removed in the last step of the Gram stain procedure developed in 1884 by the Danish
bacteriologist Hans Christian Gram (Tortora, 1998). Gram-positive cell wall contains several
peptidoglycan layers making them susceptible to the attack of penicillin. Gram-negative cell wall
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contains one or just a few layers of peptidoglycan in an intermembrane space, called periplasmic
space, between an outer membrane and the cytoplasmic membrane. The outer membrane is
impermeable to penicillin (Tortora, 1998). β-lactamase shows in the periplasmic space in Gramnegative bacteria and in the cell surface of Gram-positive bacteria (Foye, 1995).
β-lactamases are classified as Class A, B, C and D (Salverda et al., 2010). R.P. Ambler from the
Department of Molecular Biology, University of Edinburgh, proposed in 1980 the separation of
β-lactamases into two groups, namely Class A and Class B. The properties he used to classify the
β-lactamases were: “(1) isoelectric point, (2) molecular mass, (3) relative activity towards βlactams, (4) interaction with inhibitors and inactivators, (5) the nature of the active site, (6)
amino acid sequence, and (7) three-dimensional structure” (Ambler, 1980). In the Class A he
included the β-lactamases with masses around 29,000 D, Staphylococcus aureus PC1, Bacillus
licheniformis 749/C, Bacillus cereus 569/H β-lactamase I, and Escherichia coli R-TEM. In Class
B β-lactamases he included Bacillus cereus II which is a Zn2+-dependent enzyme, and with a
lower molecular weight of around 23,000 (Ambler, 1980). Class A, C (AmpC β-lactamases), and
D (Oxa β-lactamases) are serine enzymes, whereas Class B and its subgroups B1, B2, and B3 are
metallo- enzymes (Hall and Barlow, 2005).
The evolutionary relationship among enzymes in this classification is depicted in figure 4, and a
more detail phylogenic tree of class A β-lactamases is given in figure 5. The phylogenetic tree by
Hall and Barlow (2004) indicates that divergence of Class C β-lactamase came before divergence
of Class A and D β-lactamases and that they are relative to the DD-peptidases. Moreover, Class
C has evolved in the same path without splitting into other classes. This tree
is based on homology of the amino acid at positions the 3D structure of the enzyme not the
sequence, therefore, it is a structure-based tree (Hall and Barlow, 2004).
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Figure 4: Phylogenetic tree for the evolution of β-lactamases (From Hall and Barlow, 2004).
Line length does not represent time or nucleotide distance, it only represents the divergence to
different paths by the different classes of β-lactamases.
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Figure 5: Phylogenetic tree of the class A β-lactamase (From Hall and Barlow, 2004).
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Figure 5 shows the relationship among Class A β-lactamases. The scale is noted at 144
nucleotide change per length of bar. CFB group is Cytophaga-Flexibacter-Bacteroides which is
the group containing the genes CGA1, CME2, and CFXA2. Node A indicated divergence of
Gram-positive from Gram negative bacteria and then in B horizontal transfer from Gramnegative into Gram-positive bacteria. Mycobacterium tuberculosis is a Gram-positive bacterium,
and Haemophilus influenzae a Gram-negative bacterium. The TEMs and their cousin SHV1 are
from Gram-negative bacteria. TEM and the SHVs according to the tree diverged from each other
300 to 400 million years ago, the CTX-M 200 to 300 million years ago. Node A occurred 2.2
billion years ago and node B occurred 800 million years ago. Because these genes have been in
the bacteria for millions of years shouldn’t be of surprise, the fact that they are expressed as a
response to the use of β-lactam antibiotics in medicine and in agriculture. (Hall and Barlow,
2004).
The need for β-lactamase production by the antibiotic resistant bacteria is due to the work of
penicillin, as well as other β-lactams, in interfering with cell wall formation. This occurs in the
last reaction in cross-linking of the two strands of peptidoglycans: the deacylation half reaction
(Figure 5). The enzymes that catalyze the cross-linking of the peptidoglycans are penicillin
binding protein or transpeptidases (PBP). An example of PBP is the structure with accession
number 2BCF in Pubmed databases (Figure 32 a).
The sequence of events that led to this type of research is as follows: 1) Bacteria would build cell
walls with the use of the PBPs. The PBPs cross link two peptidoglycan strands in which a D-AlaD-Ala terminus is cleaved thus losing one D-Ala in a serine acylation half reaction, then in a
deacylation half reaction this D-Ala terminus would be transferred to an amine substituent in a
second peptidoglycan (Fisher et al., 2005). 2) Antibiotics, such as penicillin-G and the β-lactams
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(Figure 1), inhibit PBPs (Figure 32 a). Penicillin and the beta lactams mimic the central portion
of this newly formed peptide. The carbonyl on the C-terminus of D-Alanine is mimicked by the
lactone carbonyl of the β-lactam ring in Penicillin. Transpeptidases then acylate the lactone
carbonyl of the β-lactam ring instead of the carbonyl of the peptidoglycan (Fisher et al., 2005).
3) Bacteria respond to this attack by the β-lactams by expressing enzymes that mimic the PBPs
active site and attack the lactone carbonyl of the β-lactams hydrolyzing the amide bond of the
ring. The antibiotic would no longer resemble the junction of the peptidoglycans in the cell wall
and the PBPs carry on with acylation-deacylation reactions to cross-link the peptidoglycans.
These enzymes that mimic the PBPs are the β-lactamases (Figure 32b), and the bacteria
producing them become antibiotic resistant (Fisher et al., 2005). 4) In response to the appearance
of new β-lactamases, researchers are compelled to look for compounds that resemble the
penicillin system, but would not be hydrolyzed by β-lactamases. Boronic acids are part of such
compounds.
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Figure 6: Schematics of PBP acylation reaction (From Fisher et al., 2005). The scheme
shows the acylation half reaction in which the enzyme reacts via nucleophilic attack of the Cterminus of a D-Ala in the pentapeptide N-acetylmuramic acid (NAM) assembled with Nacetylglucosamine (NAG) as NAG-NAM and hydrolyzes the peptide bond. The resulting
acylated species is transferred to an amino group of the nearby chain. The structure in the
junction of this new peptidoglycan the D-Ala-D-Ala portion of the first strand of the
peptidoglycan and the diaminopimelate portion of the second strand is mimicked in part by βlactams. (Fisher et al., 2005)
Because of ever-evolving pathogens, it is of the highest importance to find new compounds that
would inhibit the β-lactamases.
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The PBPs and class A β-lactamases share conserved positions; they have the same amino acid
side chains in the same residue position, in the amino acid sequence (Figures 6, 7 and 8). For the
structure BlaC (accession number 3CG5) the first 40 residues are missing as a truncated leading
sequence (Tremblay et al., 2008). This is why Ser70 is Ser42 in 3CG5 (Table 5).
D-Ala-D-Ala-peptidases (DD-peptidases) or PBPs and class A β-lactamases share structural
elements in the active site which are: 1st element, Ser-Xaa-Xaa-Lys; 2nd element, Ser-Xaa-Gly;
3rd element, Glu-Xaa-Glu-Leu-Asn, and the 4th element or Omega (Ω) loop, Glu-Xaa-Glu-LeuAsn (1). (Table 5, Figures 6, 7 and 8).
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Figure 7: Sequence alignment of MX1 and 3pte as peptidases with 1btl, 1fof and 1gce as
class A, class C and Class D β-lactamases respectively (From Peimbert and Segovia, 2003).
Shaded letters indicate strictly conserved residues, homologous residues in boxes and the
triangular shapes indicate residues mutated in C library. Secondary structural elements are shown
(Peimbert and Segovia, 2003).
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Figure 8: Consensus in class A β-lactamases (From Matagne et al., 1998). It shows the
conserved residues in Class A β-lactamases. Mycobacterium tuberculosis β-lactamase shows Gly
at position 132 instead of Asn. Ser is found in Bacillus cereus III, in three carbenicillin
hydrolyzing enzymes. P. mirabillis GN79 shows Arg at position 234 instead of Lys.
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Figure 9: A class A TEM β-lactamase (From Metagne et al., 1998). The numbers indicated in
the picture correspond to conserved positions in the PBPs and the class A β-lactamases.
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1.2. The β-lactamase substrate and the mechanism of the enzyme catalyzed reaction
1.2.1 Nitrocefin as a substrate.
The natural substrates for β-lactamases are penicillins or β-lactams (Weston et al., 1998). The
structural element common to all β-lactams is the four-membered lactam ring (Figure 1) that can
either be alone or fused with another ring as in cephalosporins (Weston et al., 1998) (Figure 12) .
This lactam ring is found in nitrocefin, which is a cephalosporin.
Nitrocefin is hydrolyzed to produce absorbance at 492 nm and 494 nm as determined
spectrophotometrically. After hydrolyzing nitrocefin, the product diffuses out of the active site
producing a pale pink color.

Figure 10. Nitrocefin structure (From Calbiochem Data Sheet).
3-(2,4-Dinitrostyryl)-(6R, 7R)-7-(2-thienylacetamido)-ceph-3-em-4-carboxylic Acid, E-isomer
(EMDMillipor.com from EMD Group)
Nitrocefin belongs to the family of the cephalosporins. They contain a dihydrothiazine ring fused
to the beta lactam ring. A general structure for cephalosporins is:

Figure 11. General structure for cephalosporins (From Essack, 2001). Cephalosporins are
characterized by the β-lactam ring fused to a dihydrothiazine ring (Essack, 2001).
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1.2.2. Hydrolysis of penicillin by β-lactamase

Figure 12: Scheme for hydrolysis of a penicillin by a serine β-lactamase (Nelson and Cox,
2008).
1.2.2.1. Acylation half reaction
An ab initio quantum mechanical/molecular mechanical study (QM/MM) calculations of class A
β-lactamase acylation by Meroueh et al. (2005) determined that the long accepted acylation
model in which Glu166 acts as a general base through a conserved water molecule is in
competition with a process in which Lys73 is the base that abstracts the proton from Ser70 to
activate it for catalysis. Molecular dynamics simulations then reveal that at the next step Ser130
and Lys73 conjugated acid are the source of protons. Ser130 protonates the nitrogen of the β-
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lactam ring, Lys73 conjugated acid protonates Ser130, and Glu166 in the protonated form serves
as the ultimate proton donor. This process drives the collapse of the beta lactam ring and the
tetrahedral intermediate. According to Meroueh et al., among 133 clinical variants of TEM-1 βlactamases, no mutations are observed at Lys73 or Glu166.

Figure 13: Acylation mechanism for class A β-lactamases (From Meroueh et al., 2005).
In this study Meroueh et al., conclude that paths I and II compete for the promotion of Ser70 to
the tetrahedral intermediate.

18

1.2.2.2. Deacylation half reaction
The deacylation of class A β-lactamases was studied by Hata et al. (2006). These workers did
theoretical calculations in which they observed that Glu166 acts as a general base, Lys73 also
participates in the reaction as a proton donor to Ser70, and Ser130 acts as a bridge to C3
carboxyl of the penicillin. The C3 carboxyl group assists the deacylation by deprotonating Lys73
through Ser130, thus making it a substrate assisted reaction. In the case of cephalosporins like
nitrocefin the carboxyl group is on C4 and the distance they computed is too weak for a
hydrogen bond (3.78 Å) and for a hydrogen abstraction from the hydroxyl group of Ser130. The
more appropriate pathway is the one suggested in the substrate-independent deacylation
mechanism by Class A β-lactamase (Figure 14) as proposed by the (Hata et al., 2006).

Figure 14: Deacylation mechanism for class A β-lactamases (From Hata et al. 2006).
Glu166 as a general base catalyst, Lys73 is a co participant in the reaction, Ser130 forms a
bridge between Lys73 and C3 carboxyl group of the substrate.
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Figure 15: Substrate-independent deacylation mechanism for Class A β-Lactamases (From
Hata et al., 2006). Mechanism proposed by Fuji et al. Glu166 abstracts a proton from water and
the hydroxyl group forms the tetrahedral intermediate with Ser70 and the substrate via
nucleophilic attack. Ser130 maintains a weak hydrogen bond with the carboxyl group of the
substrate while maintaining a hydrogen bond with Lys73 but keeping it protonated. Next, Lys73
donates a proton to Ser70 to collapse the tetrahedral intermediate.
Nitrocefin, therefore, has a lower deacylation rate than the penicillins, thereby making it more
resistant to β-lactamases.
In the two schemes above no consideration was given to the role of the oxyanion hole formed by
the two hydrogens of the side chain amino groups of A237 and Ser70 that is occupied by one of
the oxygens in the tetrahedral intermediates (Meroueh et al., 2005).
Another residue of interest is Lys234. According to Lamotte-Brasseur et al. (1999), who
performed continuum electrostatic calculations, Lys234 may play a role in the stabilization of the
tetrahedral complex because shows an increase in pKa value in the range of 11.1 to 12.0 in
TEM-1 and B. licheniformis β-lactamases in the absence and presence of ligands such as
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benzylpenicillin, cephalotin, benzylpenicillin methyl ester, cephalosporin lactone, benylpenicillin
tetrathedral intermediate.

Figure 16: Scheme showing a class A β-lactamase active site and its substrate (LamotteBrasseur et al., 1999).
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1.3. Boronic Acids as potential inhibitors of Mycobacterium tuberculosis and Bacillus cereus
569/H9 β-lactamases.
Boronic acids could be used as inhibitors of β-lactamases because Boron easily interconverts
between sp2 and sp3 hybridization forms. In sp3 hybrid a boronic acid mimics the transition state
the of enzyme-β-lactam complex in the tetrahedral structures of the half acylation reaction in the
active site (Hall, 2005) (Figure 25 and 26). Boronic acids show reversible competitive inhibition
(DeSoyza, 1990) (Weston et al., 1998).

Figure 17: Ionic equilibrium of boronic acid in water (From Hall, 2005).

Figure 18. Boronic acids as transition state analogues (From Weston et al., 1998). maminophenylboronic acid (MAPB) compared to a presumed transition-state structure during
acylation (Weston et al,. 1998) (Steinberg, 1964) (Usher, 1998).
Boronic acids are also of interest for safety reasons:
Boronic acids have low toxicity compared to other organic compounds, they show no particular
threat to the environment, small water soluble boronic acids are excreted unchanged by the
kidney, large fat soluble boronic acids are moderately toxic, and they are not readily oxidized in
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air or aqueous conditions since the coordination of water or hydroxide ions with boron protects
them against any attack by oxygen (Hall, 2005). The first serine protease boron based inhibitor
that found its way into the market was a dipeptidyl boronic acid inhibitor under the trademark
Valcade in 2003 (Gonzales, 2012) which is currently used in the treatment of multiple myeloma
(Hall, 2005).
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2. Materials and Methods
2.1. Kinetic Studies.
To determine the inhibitory efficacy against β-lactamase a thermodynamic constant is used: the
thermodynamic inhibitor dissociation constant (Ki) (www.bio.cmu.edu) (Eisenberg, 1979)
(Philipp, 1971).
starting with the classical equation for competitive inhibition: (University of Virginia website)
Vi = Vmax [S] / ( Km (1+ [I] / Ki ) + [S] ) where Vi is velocity of the inhibited reaction.
Vu = Vmax [S] / ( Km + [S] ) where Vu is the velocity of the uninhibited reaction.
when Km >> [S] these simplify to
Vi = Vmax [S] / ( Km (1+ [I] / Ki ) )
Vu = Vmax [S] / Km
dividing Vu by Vi, we have
Vu / Vi = ( Vmax [S] / Km ) / (Vmax [S] / (Km ( 1 + [I] / Ki ) )
or
Vu / Vi = ( 1 + [I] / Ki )
Vu / Vi - 1 = [I] / Ki
we arrive at:
Ki = [I] / ( Vu / Vi - 1 )

Equation (1)

Where:
[I]: Molar inhibitor concentration.
Vu: Initial velocity of the uninhibited reaction which is the slope of the curve in the first 10
minutes of the reaction.
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Vi: Initial velocity of the inhibited reaction which is the slope of the curve in the first 10 minutes
of the inhibited reaction.
When de reaction was run to completion the formula used was:
Ki = [I] / ( ku / ki - 1 )

Equation (2)

ku: Rate constant of the uninhibited reaction equal to the slope of the line formed by the points
calculated from ln(A – Max A) (Clement, 2006)
ki: Rate constant of the inhibited reaction equal to the slope of the line formed by the points
calculated ln(A – Max A) (Clement, 2006)
A: Absorbance.
ln: natural logarithm.
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2.1.1. Kinetic Studies of Boronic Acids against BlaC with Nitrocefin as Substrate.
2.1.1.1. Preparation of Boronic acids.
Stock solutions of Boronic acids from various vendors were prepared by dissolving
approximately 10.0 mg of Boronic acid in 100 mL of Dimethylsulfoxyde (DMSO) 99.8% CAS
67-68-5 from EMD

and 900 µL of pH 7.00 buffer of potassium dihydrogen phosphate /

dipotassium hydrogen phosphate at ionic strength of 0.1 M. for a total of 1000 µL. In the case
whereby the boronic acid salted out when the phosphate buffer was added, then the stock
solution was prepared in DMSO (99%).

2.1.1.2. Preparation of Nitrocefin as substrate.
Stock Nitrocefin was prepared per instructions from the manufacturer at a concentration of 1 mM
in pH 7.00 phosphate buffer ionic strength 0.1 M and kept refrigerated for later use. Nitrocefin
was diluted to 0.5 mM before the assay.

2.1.1.3. Preparation of enzyme.
1 mL aliquots of Mycobacterium tuberculosis BlaC enzyme at 6.36 µM were received as a gift
from Dr. Janet Gonzales from this lab. Subsequently, 1-mL aliquots of 300 µM concentration
were prepared by diluting 47.2 µL of BlaC enzyme in 952.8 µL of phosphate buffer at pH 7.0,
for a total of 1000 µL.

2.1.1.4. Preparation of buffer.
Phosphate buffers were prepared at ionic strength of I = 0.1 M as prescribed by the Biochemistry
Handbook (Long, 1961).
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2.1.1.5. Spectrophotometry
A Synergy multi-detection microplate reader (Biotek), was attached to a Dell personal computer
for kinetic experiments. Data was collected using Gen5 Microplate Data collection and analysis
software and saved as Excel files.
The wavelength used in this experiment was 494 nm as previously determined by a difference
spectrum analysis of hydrolyzed and unhydrolyzed Nitrocefin. The experiments were set to run
for 10 minutes and set the data collection at a minimum interval determined by the microplate
reader varying from 8 to 12 seconds depending on the number of wells utilized for the
experiment. The kinetic experimental results were subsequently analyzed by linear regression
analysis and the Ki was determined according to equation (1) above.

2.1.1.6. Experiment set up
Cocktails were prepared in the microplate for a final concentration for BlaC enzyme of 24.0 nM;
nitrocefin, 40 µM and the inhibitors at the indicated concentration millimolar concentrations.
DMSO (10% v/v) solvent was added to the uninhibited reaction in equal amount as of the
boronic acid solution as in the inhibited reaction.
The amounts where: enzyme, 20.0 µL; DMSO, 20 µL or boronic acid, 20 µL and buffer, 190 µL
and nitrocefin 20 µL for a total well volume of 250 µL.
The order of application to the well was buffer, DMSO or inhibitor, nitrocefin and finally the
enzyme.
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2.1.2. Boronic Acids as Inhibitors of β-lactamase from Bacillus cereus 569/H9 I.
2.1.2.1. Preparation of enzyme.
A vial of Bacillus cereus 569/H9 (Calbiochem) containing 779.56 units of β-lactamase I and
75.28 β-lactamase II was dissolved in 2.0 mL of potassium dihydrogen phosphate/ potassium
hydrogen phosphate buffer at pH 7.0 and I = 0.1 M and subsequently diluted to make 100
aliquots of 3.886 µM enzyme as stock solution. The concentration of the enzyme in the stock
solution was determined as follows: The ExPASy ProtParam tool was utilized to get the
extinction coefficient of the enzyme 28085 for the molecular weight of 31, 557.2 the closest to
the reported value by Calbiochem of 31500 M.W. meaning we have a match.
Scanning the an aliquot of the vial from Calbiochem, it was determined that β-lactamase I had a
concentration of 170 µM total.

2.1.2.2. Spectrophotometry.
A UV/VIS Spectrophotometer model Lambda 2 from Perkin-Elmer Corporation., equipped with
Perkin Elmer WinLab PECSS software was utilized for these experiments. A quartz cuvette of
2.0 mL capacity was utilized for the reaction mixture. Temperature in the reaction mixture was
maintained at 25 ˚C with the help of a water bath system equipped with a VWR heater (VWR
Scientific, San Francisco, CA). Data points were taken every 10 seconds and the visible light
lamp set at 494 nm.
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2.1.2.3. Experiment set up.
Cocktails were prepared in a 2 mL quartz cuvette for a final concentration for TEM-1 enzyme
1.62 µM; Nitrocefin, 16.2 µM (68% of Km). Km reported in the literature was 24 µM
(Villacorta, 1991). The inhibitors were added in various concentrations depending on the
inhibitor, buffer final concentration was kept at 0.1 molar. The volumes added to the cuvette
were: enzyme, 430.0 µL; 37.6 µL DMSO or boronic acid, 500 µL buffer and 32.4 µL nitrocefin
for a total cuvette volume of 1000 µL.
The order of application to the well was buffer, DMSO or inhibitor, nitrocefin and finally the
enzyme. The absorbance at 494 nm was taken and a progress curve of product formation was
recorded. When the plateau of the absorbance curve was reached (around 60 minutes or more)
the experiment was stopped. The data was transferred to an Excel worksheet where the formula
Ln(At-A∞) was applied. A linear regression analysis was performed on the data. The absolute
value of the slope was taken as reaction rate, ku for uninhibited and ki for the inhibited reaction.
Then Ki was found with the formula:
Ki = [I]/((ku/ki)-1).

2.1.2.4. Disabling β-Lactamase II (metallo-enzyme) from Bacillus cereus 569/H9.
Ethylenediaminetetraacetic Acid (EDTA) was used at concentration of 1 mM to completely
inhibit β-Lactamase II present in the vial (Calbiochem). In kinetic experiments EDTA
concentration was maintained 5 fold to 10 fold greater than that of β-lactamase II.
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2.2. Modeling in silico the inhibitor-enzyme complex in the inhibition of β-lactamases by
boronic acids.
2.2.1. Selection of the Mycobacterium tuberculosis (BlaC) β-lactamase x-ray structure for
modeling studies.
The first β-lactamase used was provided by Dr. Douglas S. Kernodle, M. D., Vanderbilt
University School of Medicine, Division of Infectious Disease, Nashville, TN. USA, as a gift to
Dr. Janet Gonzalez of this lab in a host for the recombinant protein E. coli Top10 (Invitrogen).
This host contained the plasmid pTrcHisB (Invitrogen) expressing the gene BlaC in cosmid Y-49
a class A β-lactamase, from an attenuated Mycobacterium tuberculosis strain Rv37a (Voladri et
al., 1998). Dr. González, provided me with the purified enzyme that I needed for my project. Dr.
Douglas S. Kernodle provided Janet with the amino acid sequence:
MRNRGFGRRELLVAMAMLVSVTGCARHASGARPASTTLPAGADL
ADRFAELERRYDARLGVYVPATGTTAAIEYRADERFAFCSTFKAPLVAAVLHQNPLTH
LDKLITYTSDDIRSISPVAQQHVQTGMTIGQLCDAAIRYSDGTAANLLLADLGGPGGG
TAAFTGYLRSLGDTVSRLDAEEPELNRDPPGDERDTTTPHAIALVLQQLVLGNALPPD
KRALLTDWMARNTTGAKRIRAGFPADWKVIDKTGTGDYGRANDIAVVWSPTGVPYVV
A VMSDRAGGGYDAEPREALLAEAATCVAGVLA
GenBank accession number Z73966.
BLAST search was conducted using the National Center for Biotechnology Information (NCBI)
database (Figure 18).
NCBI BLAST search showed that the sequence is part of the β-lactamase super family (Figure
19) and then gave me an option to select among structures available in its data banks that are
100% identical to the sequence provided. 3CG5 was because it has a 100% identity and it
contained an inhibitor (clavulanate) in the active site. According to Dr. Blanchard (Tremblay et
al., 2008) the source for this crystal structure was the blaC gene amplified from genomic
Mycobacterium tuberculosis H37Rv which is identical to that of Rv37a per Dr. Kernodle
(Voladri et al., 1998). According to Dr. Blanchard BlaC was expressed as an N-terminally
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truncated form that missed the first 40 amino acids and this is why Ser42 in 3CG5 correspond to
Ser70 in the class A β-lactamases.
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Figure 19: 3CG5 and the sequence provided by Dr. Kernodle. Note 100 % homology.
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2.2.2. Selection of the Bacillus cereus 569/H9 β-lactamase x-ray structure for modeling
studies.
β-lactamase Bacillus cereus was searched in the protein data bank of NCBI and one of the
sequences, Bacillus cereus a non-metallo β-lactamase was the sequence in GenBank accession
number ACV20891.1 a TEM enzyme per comments by the authors in NCBI. I searched in
NCBI protein structures for a TEM enzyme. NCBI accession number 1ERO is a TEM-1 enzyme,
it contains a boronic acid in its active site reason why it was selected. A Clustal sequence
alignment between ACV2089.1 and 1ERO reveal two substitutions. V84I and A184V:
ACV20891.1 Ile84 corresponds to Val84 in 1ERO and Val184 in ACV20891.1 corresponds to
Ala184 in 1ERO. These variants of TEM-1 are found in TEM-116 (Hu et al., 2007, Lahey clinic
website). Only the TEM-1 structure was located at NCBI.

Figure 20: NCBI search for “β-lactamase Bacillus cereus”. Search results in GenBank:
Accession number ACV2089.1 and FASTA sequence.
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2.2.3 Docking Procedure
2.2.3.1. Preparation of the enzyme
A pdb file was downloaded from NCBI (for example 3CG5) with Sculpt from MDL. With
NotePad from Microsoft the water molecules were deleted. Swiss-PdbViewer was used for
adding all the protons to the enzyme except the one in Ser42 (70) γO that was deleted. The
Sculpt format is maintain by opening the pdb file and saving it with Sculpt. EasyConvert (EC)
from AutoDock Vina was used for converting the pdb to pdbqt file which is a pdb formated for
AutoDock Vina.
2.2.3.2. Preparation of the boronic acids structures for docking.
Drawings were made of boronic acids with Draw 2.5 from MDL. Carbon was utilized instead of
boron for purposes of docking. 3D optimization and hydrogens were obtained using ACD/Chem
Check Freeware from Advance Chemistry Development then saved as a “.mol” file.
The “.mol” file was converted to a “.pdb” file using Open Babel from OpenBabelGUI by Chris
Morley (www.openbabel.org). Finally the “.pdb” file was converted to a “.pdbqt” file using EC
as in preparation of the enzyme above.

2.2.3.3 Conducting the in silico experiment.
The enzyme “.pdbqt” and the boronic acid “.pdbqt” were dragged to AutoDock Vina utility
(Pcvt). The program returned nine possible docking outcomes or less, each with a ΔG. AutoDock
Vina suggests the best docking result per lowest ΔG . Coordinates were for the active site known,
gamma serine 42 in the case of 3CG5 or serine 70 in the case of 1ERO was set as the coordinates
in a grid size of 10 Angstroms. If the coordinates were not entered the inhibitor could go
somewhere else other than the active site. The coordinates for Ser42(70) γO in 3CG5 were:
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-11.982, -10.876, 6.645 and for 1ERO 38.287, 37.117, 30.517. The above parameters were
found in the pdb file.
After docking, the original protonated pdb file of the enzyme was merged with the dokcing pdb
file for the small molecule given by AutoDock Vina using Swiss-PdbViewer. Sculpt was used to
identify and map the active site by throwing a surface in a 10.0 Å sphere around the inhibitor.
Discovery Studio visualizer was for determining the important interactions such as hydrogen
bonding and pi stacking.

2.2.3.4 Computation of Ki from ∆G (affinity constant) from AutoDock Vina.
ΔG = - RTlnK, where K = association constant (Eisenberg, 1979).
K = e-(ΔG/RT) Where K is an association constant. Then Ki would be 1/K and the formula is
Ki = (1/ e-(ΔG/RT))x106 in order to express the value in the micromolar units (University of Oulu
website).
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3. Results
3.1. Kinetic results
3.1.1. Selection of kinetic wavelength.

Difference Spectrum of Hydrolyzed and Unhydrolyzed
Nitrocefin

Absorbance (Abs)
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0.09

0.04

-0.01
350

400

450
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600

Wavelength (nm )
Unhydrolyzed

Hydrolyzed

Difference

Figure 21: Difference Spectrum of Nitrocefin unhydrolyzed and hydrolyzed. Maximum
difference is at 494 nM . Enzyme used was BlaC. Nitrocefin was purchased in Calbiochem
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3.1.2. Effect of EDTA on β-lactamase from Bacillus cereus 569/H9.
In the graph in (Figure 28) it can be observed that EDTA inhibits the mixture of enzymes βlactamase I and β-lactamase II (Calbiochem). That the inhibition does not increase by a great
margin as the concentration of EDTA is increased, and that there is a reduction of hydrolysis that
can be visually assessed to be approximately 10 % which is the content of β-lactamase II (the
metallo-enzyme) in the vial. The total units in the vial is 854.84 units; β-lactamase I units in the
vial are 779.56 (91 % of total) and the β-lactamase II units in the vial are 75.28 units (9 % of
total). A characteristic of metallo-enzymes that sets them apart from the other classes of βlactamases is their sensitivity toward EDTA (Chakraborty et al., 2010)
In figure 29 we can see that the effect of EDTA is constant as one of the enzymes is disabled and
does not affect the other enzyme.
EDTA Effect on Beta_lactamase from B. cereus
Beta_lactamase = 1.62 uM; Nitrocefin 16 uM
0.35
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10 uM EDTA
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No EDTA trial 2

Figure 22: EDTA effect on the activity of β-lactamase from Bacillus cereus 569/H9.
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EDTA Effect on Betalactamase from B. cereus
Enzyme = 0.32 uM; Nitrocefin = 16 uM
0.4

K(obs)

0.3
0.2
0.1
0.0

0

2

4

6

8

10

EDTA uM
Figure 23: EDTA effect on the activity of β-lactamase from Bacillus cereus 569/H9
(Calbiochem). Vial contains serine β-Lactamase I 779.56 units/vial; Metallo β-Lactamase II
75.28 units/vial. EDTA inhibits the metallo-enzyme but not the serine β-Lactamase.
K(observed) was computed and plotted in GraphPad Prism 5.03 from GraphPad Software, Inc.
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3.1.3 Kinetic run results
3.1.3.1. Kinetics results for BlaC.
Table 1: Results for boronic acids as inhibitors of BlaC.
Vina's
Ki (µM) ΔG **

Boronic Acid
3,4,5-Trifluorophenylboronic acid
3-Nitrophenylboronic acid
2,3,4,5-Tetrafluorophenylboronic acid
3,5-Bis(trifluoromethyl)benzeneboronic acid
2,3,5-Trifluorophenylboronic acid
2-Carboxythiophene-5-boronic acid
5-Trifluoromethyl-1,3-phenyldiboronic acid
3-Chloro-4-fluorobenzeneboronic acid
3-carboxy-5-nitrophenylboronic acid
3-Carboxy-4,5-difluorophenylboronic acid
4-Bromophenylboronic acid
Diphenylborinic anhydride
2,3,4,6-Tetrafluorophenylboronic acid
4-Chlorobenzeneboronic acid
2-Phenyl-1-ethynylboronic acid pinacol ester
2,4,6-Trifluorophenylboronic acid
Phenylboronic acid

176
214
229
302
477
493
644
658
845
1469
1919
2043
2184
2581
5277
5999
6364

-5.9
-6.3
-6.0
-3.4
-5.7
-5.6
-4.4
-5.6
-4.5
-6.1
-5.3
-6.2
-5.4
-5.3
-5.4
-5.5
-5.6

Vina’s
Ki (µM)
47
24
40
3207
66
78
592
78
500
34
130
28
109
130
109
92
78

*

*
*
*
*
*
*
*
*

Table 2: Non-boronic compounds as inhibitors of BlaC.

4,4'-DDT
Quinine Hydrochloride

Vina’s
Vina's Ki
Kinetics Ki (µM) ΔG
(µM)
48
-6
40
2452
10.5 >10000 *

* Preliminary data, more tests needed for marked compounds.
** All ΔG reported in this dissertation are in kcal/mol.
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3.1.3.2 Kinetic results for β-lactamase I from Bacillus cereus 569/H9 TEM-116
Table 3: Boronic acids as inhibitors of β-Lactamase I from Bacillus cereus 569/H9 TEM116 (kinetics) and TEM-1 (in silico).
Vina's
Vina’s
Compound name
Ki (µM)
ΔG
Ki (µM)
2-Carboxythiophene-5-boronic acid
1.1
-5.3
130
3-Carboxyphenylboronic acid
19.4
-6.2
28
2-Carboxythiopehene-4-boronic acid
46.5
-5.9
47
3-Carboxy-4-fluorophenylboronic acid
47.1
-5.6
78
3-carboxy-5-nitrophenylboronic acid
65.8
-3.9
1378
3-Amino-5-carboxylphehylboronic acid
136.9
-5.1
182
3-Nitrophenylboronic acid
247.3
-6.1
34
2,3,5-Trifluorophenylboronic acid
394.6
-5.4
109
2,3,4,5,6-Pentafluorobenzeneboronic acid
461.5
-4.5
500
2,3,4,6-Tetrafluorophenylboronic acid
573.6
-5.4
109
2-Phenyl-1-ethynylboronic acid pinacol ester
848.0
0.1
>103
3-Pyridineboronic acid
1063.0
-4.9
255
2,3,4,5-Tetrafluorophenylboronic acid
1121.0
-4.8
301
3-Chloro-4-fluorobenzeneboronic acid
1163.0
-4.9
255
3-carboxytiophene-2-boronic acid
1337.0
-5.6
78
2,4,6-Trifluorophenylboronic acid
1663.0
-5
215
Phenylboronic acid
2998.0
-4.9
255
3,4,5-Trifluorophenylboronic acid
7228.0
-5.2
153
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3.2. Sequence alignments and computer modeling results
3.2.2. Finding differences and homology between one peptidase and the two enzymes
available in the present research.

Figure 24: Multiple Sequence Alignment of a PBP (2BCF), BlaC (3CG5) and TEM-1
(1ERO). Asterisks: Conserved residues in all three enzymes (Clustal Omega).
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Figure 25: Clustal sequence alignment of 3CG5 and 1ERO transcribed to Excel.
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Table 4: Consensus, motifs (or elements), BlaC (3CG5), TEM-1 (1ERO) compared.
Element
(charge)
I
SxxK

/

Motif
Amino acid

3CG5 position

Consensus *

1ERO position

(+1)
SER
THR
PHE
LYS

42
43
44
45

70
71
72
73

70
71
72
73

II
(-1)
SDN or

SER
ASP

100
101

130
131

SDG

GLY

102

132

130
131
ASN
132

LYS

208

234

THR
GLY

209
210

235
236

234
SER
235
236

GLU
PRO
GLU
LEU
ASN

140
141
142
143
144

166
167
168
169
170

166
167
168
169
170

III
KTG

(+1)

IV
(-2)
(In Omega loop)
ExELN

* Consensus (Metagne et al., 1998).
In Table 4 is presented further results of the alignment of the two β-lactamases in this research
and the consensus reported by Metagne et al., (1998). The electrical charges found in the motifs
are stated per Verma et al., (2013). Keeping in mind the net electrostatic charges of the elements
that comprise the active site pocket may assist us in selecting specific groups for substituents in
the aromatic ring of the inhibitor. The 4th element is imbedded in the Ω-loop that comprises
sixteen residues in the form xRxExxLNxxxxxxxx (Verna et al,. 2013).
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Figure 26: 3CG5 (red) superposition on 1ERO (blue) in Sculpt. Model made in Sculpt as a
result of a sequence alignment submitted to SDS CD-EMC server from University La Sapienza
of Rome (http://schubert.bio.uniromal.it/CEMC/)
In figure 35 one can see a near perfect alignment of the backbones of BlaC (3CG5) and TEM-1
(1ERO) can be observed. They were submitted for alignment to the server at University La
Sapienza (Rome) through their website.
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3.2.4. Modeling of inhibitors in the active site of BlaC and TEM-1 β-lactamases.
3,4,5-Trifluorophenylboronic acid in the active site of BlaC (3CG5) and TEM-1 (1ERO).

Figure 27: 3,4,5-Trifluorophenylboronic acid in the active site of BlaC (3CG5) (top) and
TEM-1 (1ERO) (bottom) (See appendix E for color code).
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Table 5: 3,4,5-Trifluorophenylboronic acid in BlaC (3CG5) and TEM-1 (1ERO). Important
interactions.
3,4,5-Trifluorophenylboronic acid
BlaC

TEM-1

Å
3.65

Å
5.09

2.42
2.71

-

1.90

-

-

2.12

-

2.35

-

2.44

2.10

-

3CG5(1ERO)
Ser42(70)
Ile75 Tyr(105)
Ile75 Tyr(105
Ser100(130)
Ala217 Arg(243)
Thr209 Ser(235)
Thr209 Ser(235)
Thr211 Ala(237)

Side chain Oxygen to Boron
Hydrogen bond to ligand's
Fluorine C(4) of ring
Pi stacking - distance to C(3)
Hydrogen bond to ligand's
boronate hydroxyl
Hydrogen bond to ligand's
boronate hydroxyl
Hydrogen bond to ligand's
boronate hydroxyl
Hydrogen bond to ligand's
boronate hydroxyl
Hydrogen bond to ligand's
boronate hydroxyl
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3,4,5-Trifluorophenylboronic acid in the active site of BlaC (3CG5).

Figure 28: 3,4,5-Trifluorophenylboronic acid in BlaC active site of BlaC. Surface on within a
10.0 Å sphere of the inhibitor. All amino acids that are within 10 Å from the inhibitor show on a
list on the side.
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Figure 29: 3,4,5-Trifluorophenylboronic acid in the active site of BlaC (3CG5). Distances
between Ser42(70) and the inhibitor.
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Figure 30: 3,4,5-Trifluorophenylboronic acid (ball and sticks) in the active site of BlaC
(3CG5). Surface on within 5 Å of the inhibitor. Ile75 is the only amino acid in this sphere.
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Figure 31: 3,4,5-Trifluorophenylboronic acid in the active site of BlaC (3CG5). Ile75 is
located on the left, ligand in the middle and Ser42 on the right.
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Figure 32: 3,4,5-trifluorophenylboronic acid in the active site of BlaC (3CG5). Ile75 shows
as the protuberance on the left of the benzene ring of the inhibitor.
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Figure 33: 3,4,5-Trifluorophenylboronic acid in the active site of BlaC (3CG5). Distances
between Ile75 and the inhibitor.

52

Figure 34: 3,4,5-trifluorophenylboronic acid in the active site of BlaC (3CG5). Surface on
within 6 Å of the inhibitor. Ser42(70), Ser100(130) and Thr211 (Ala237) are the surface in the 6
Å sphere.

53

Figure 35: 3,4,5-trifluorophenylboronic acid in the active site of BlaC (3CG5). Distances
between Ser100(130), Ser42(70), and Thr211 (Ala237) and the inhibitor.
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Figure 36: 3,4,5-trifluorophenylboronic acid in the active site of BlaC (3CG5). Included
Ser42(70) for reference. Hydrogen bond possible between Gly102(132) N terminus Hydrogen
and F(5) of ligand 3.43 Å and another hydrogen bond possible between Asn144(170) γNH and
F(3) of ligand 3.08 Å. 7 Å sphere around the inhibitor.
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Figure 37: 3,4,5-trifluorophenylboronic acid in the active site of BlaC (3CG5). Amino acids
in the 8 Å sphere around the inhibitor. Lys45, Ser74, Glu140 and Gly210. The relevant possible
interactions are Hydrogen bonds between δ Hs and F(3) measuring 3.23 Å and 3.52 Å of Glu140
and 3.38 Å to the F(4). Also Lys45 ε H and F(3). Ser74 β H to F(3) 3.93 Å
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Figure 38: 3,4,5-trifluorophenylboronic acid in the active site of BlaC (3CG5). Amino acids
in the 9 Å sphere around the inhibitor. No relevant distance noted. Ser76 N-terminus H with F(5)
5.74 Å and β H with F(5) 5.92 Å
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Figure 39: 3,4,5-trifluorophenylboronic acid in the active site of BlaC (3CG5). Amino acids
in the 10 Å sphere around the inhibitor.
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Figure 40: 3,4,5-Trifluorophenylboronic acid in the active site of BlaC (3CG5). Ile75
distance to the ring 2.71 Å and 2.43 Å from αNH(H) to F(4) in the inhibitor.
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3,4,5-Trifluorophenylboronic acid in the active site of TEM-1 (1ERO).

Count

Figure
3,4,5-Trifluorophenylboronic
acid in the active site of TEM-1 (1ERO). Surface
1ERO_p
and 41:
3,4,5-Trifluorophenylboronic
acid (BA49)
on inwithin
10.0 Åaway
of the
List of amino acids in the 10.0 Å sphere from the inhibitor
Surface
Angstroms
fro inhibitor.
the ligand.
6.0 right. 7.0
8.0
9.0
10.0
shown in the 5.0
window at the
GLY
236
ALA
237
SER
70
SER
130
SER
235
TYR
105
VAL
216
MET
69
LYS
234
GLY
238
ARG
243
THR
71
MET
129
ASN
132
ASN
170
GLY
244
LYS
73
ASP
131
ALA
217
MET
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Figure 42: 3,4,5-Trifluorophenylboronic acid in the active site of TEM-1 (1ERO). Distances
between Ser70 and Ser235 and the inhibitor.
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Figure 43: 3,4,5-Trifluorophenylboronic acid in the active site of TEM-1 (1ERO). Distances
between Asn132 and Arg243 with the inhibitor. Ser70 and Ser235 are shown for reference.
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Figure 44: 3,4,5-Trifluorophenylboronic acid in the active site of TEM-1 (1ERO). Distances
between Tyr105, Asn170, Val216, Met270 and the inhibitor.
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Figure 45: 3,4,5-Trifluorophenylboronic acid in the active site of TEM-1 (1ERO). Space
filling model of Tyr105, Asn170, Val216, Met270 and the inhibitor in the active site.
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3-Nitrophenylboronic acid in the active site of BlaC (3CG5) and TEM-1 (1ERO).

Figure 46: 3-Nitrophenylboronic acid in the active site of BlaC (3CG5) (top) and TEM-1
(1ERO) (bottom).
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Table 6: 3-Nitrophenylboronic acid in BlaC (3CG5) and TEM-1 (1ERO) active sites. Important
distances.
3-Nitrophenylboronic acid
3CG5(1ERO)
Ser42(70)
Lys45(73)
Ile75 Tyr(105)
Asn144(170)
Lys208(234)
Thr209 Ser(235)
Thr211 Ala(237)
Ala217 Arg(243)

BlaC
BlaC
TEM-1
Side chain Oxygen to Boron
NH(H) to C(1) Pi
NH(H) to C(2) Pi
C(3) to C(4)
N(H) to OH(O) H-b
αN(H) to OH(O)
N(H) to C(3)
OH(H) to NO(O) H-b
OH(H) to NO(O) H-b
NH(H) to NO(O) H-b

Å
3.64
4.19
3.14
2.46
4.91
2.07
2.11

TEM
-1
Å
3.29
3.50
1.82

2.43

See page 82 (Table 8) for abbreviations.
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3-Nitrophenylboronic acid in the active site of BlaC (3CG5).

Figure 47: 3-Nitrophenylboronic acid in the active site of BlaC (3CG5). Surface on within
10.0 Å of the inhibitor. A list of amino acids in the 10.0 Å sphere from the inhibitor is shown in
the window at the right.
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Figure 48: 3-Nitrophenylboronic acid in the active site of BlaC.
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TEM-1 and 3-Nitrophenylboronic acid

Figure 49: 3-Nitrophenylboronic acid in the active site of TEM-1 (1ERO). Surface on
within 10.0 Å of the inhibitor. A list of amino acids in the 10.0 Å sphere from the inhibitor is
shown in the window at the right.
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Figure 50: 3-Nitrophenylboronic acid in the active site of TEM-1. Distances of Ser70,
Tyr105, Asn170, and Arg243 to the inhibitor.
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Figure 51: 2,3,4,5-Tetrafluorophenylboronic acid in the active site of BlaC (3CG5).
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Table 7: 2,3,4,5-Tetrafluorophenylboronic acid in the active site of BlaC (3CG5).
2,3,4,5-Tetrafluorophenylboronic
acid
Sculpt
Sphere
3CG5
(A)
Element
Ser
100 6
2
Thr
211 6
Thr
211 6
Ser
100 6
2
Ile
75 5
Ser
42 6
1
Asn
144 7
4
Gly
102 7
2
Ser
42 6
1
Ile
75 5
Gly
210 8
3
Lys
45 8
1
Ser
42 6
1
Pro
141 9
4
Ser
76 9
Asp
101 9
2
Leu
143 9
4

H-b per
Discovery
Studio
y
y
y
y
y
y

H-b
criteria
Distance Ser42
Inhibitor <4.0
1.90
OH(O) OH(H)
yes
2.10
αNH(H) OH(O)
yes
2.39
αCO(O) OH(H)
yes
2.40
OH(H) OH(O)
yes
2.42
αNH(H) C'4F
yes
2.92
O
OH(H)
yes
3.02
NH(H) C'3F
yes
3.36
αNH(H) C'3F
yes
3.48
αNH(H) OH(O)
yes
2.66
βH
C'3
2.94
αH
OH(H)
3.29
NH(H) C'2
3.46
O
B
3.71
βH
C'3F
5.29
αH
C'3F
5.74
αCO(O) C'2H
6.02
δH
C'3
-

See page 82 (Table 8) for abbreviations.
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Figure 52: 2,3,4,5-Tetrafluorophenylboronic acid and the active site of BlaC. Distances
between Ser42, Ile75, Ser100, Thr211 and the inhibitor. Dotted lines in green are hydrogen
bonds calculated by Swiss-PdbViewer.
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Figure 53: 2,3,4,5-Tetrafluorophenylboronic acid and the active site of BlaC. Ile75(105)
shows in the first sphere around the ligand that is 5 Å from the ligand. (Sculpt)
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Figure 54: 2,3,4,5-Tetrafluorophenylboronic acid and the active site of BlaC. Ile75(105)
shows in the first sphere around the ligand that is 5 Å from the ligand. (Swiss-PdbViewer)
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Figure 55: 2,3,4,5-Tetrafluorophenylboronic acid and the active site of BlaC. Distances
between residues that show in Sculpt at 6 Å sphere around the inhibitor.
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Figure 56: 2,3,4,5-Tetrafluorophenylboronic acid and the active site of BlaC. Distances
between residues that show in Sculpt at 7 Å from the ligand.
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Figure 57: 2,3,4,5-Tetrafluorophenylboronic acid and the active site of BlaC. Distances
between residues that show in Sculpt at the 8 Å sphere around the inhibitor.
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Figure 58: 2,3,4,5-Tetrafluorophenylboronic acid and the active site of BlaC. Distances
between residues that show at the 9 Å sphere around the inhibitor in Sculpt.
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3,5-Bis(trifluoromethyl)phenylboronic acid in BlaC (3CG5).

Figure 59: 3,5-Bis(trifluoromethyl)phenylboronic acid in the active site of BlaC (3CG5).
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Table 60: 3,5-Bis(trifluoromethyl)phenylboronic acid in BlaC (3CG5). Surface on within
10.0 Å of the inhibitor. A list of amino acids in the 10.0 Å sphere from the inhibitor is shown in
the window at the right.
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Table 8: 3,5-Bis(trifluoromethyl)phenylboronic acid in BlaC.
Sculpt
H-b per
Sphere Element Visualizer Distance
(Å) *
**
§
(Å)
Enzyme Inhibitor
5
1.35 αNH(H) mF
6
y
1.67 αNH(H) OH(H)
5
y
1.71 αNH(H) mF
6
1 y
1.96 γO
OH(H)
7
3
2.83 αCO(O) OH(H)
6
2
3.16 γO(H)
mF
6
4
1.77 δN
C’2H
8
2.00 βH
mF
7
2.37 βH
OH(O)
7
4
2.94 δO
C’2H
6
1
3.03 γO
B
7
3.48 αH
mH
8
1
3.86 εNH(H) C’1
9
4
4.13 βH
mF
9
3
4.24 βOH(H) mF
10
4.28
9
2
4.68
8
4
4.97
7
2
5.05
9
5.32
10
3
5.58
10
1
5.64
10
5.64
10
5.70
10
6.73

Residue
3CG5
Number
H-b
Ile
75
yes
Thr
211
yes
Ile
75
yes
Ser
42
yes
Gly
210
yes
Ser
100
yes
Asn
144
Ser
74
Cys
41
Glu
140
Ser
42
Gly
212
Lys
45
Pro
141
Thr
209
Pro
77
Asp
101
Leu
143
Gly
102
Ser
76
Lys
208
Thr
43
Ala
105
Arg
145
Asp
213
mF: Methyl fluoride.
C’2: Carbon 2, starting from the junction with the rest of the molecule, in the ring.
βH: Hydrogen in the β carbon.
εNH(H): The hydrogen in the epsilon amino group takes part in this bond.
αNH(H): The hydrogen in the backbone amino group takes part in this bond.
αCO(O): The oxygen of the carboxyl end of the residue takes part in this bond.
OH(H): The hydrogen of one of the hydroxyl groups in the boronic acid takes part in the bond.
OH(O): The oxygen of one of the hydroxyl groups in the boronic acid takes part in the bond.
B: Boron.
H-b: Hydrogen bond.
*: Sculpt Sphere in Å: When surface on is activated in Sculpt at the indicated number, the residue
in the line appears as part of the surface.
**: This amino acid belongs to the element indicated, in accord with table 4.
§: “y” indicates that per Discovery Studio Visualizer this link shows as a hydrogen bond.
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Figure 61: 3,5-Bis(trifluoromethyl)phenylboronic acid in BlaC. Ile75(105) is the closest
amino acid at to the ligand at 5 Å away.
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Figure 62: 3,5-Bis(trifluoromethyl)phenylboronic acid in BlaC. Ile75(105) is the closest
amino acid at to the ligand at 5 Å away.
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Figure 63: 3,5-Bis(trifluoromethyl)phenylboronic acid in BlaC. Thr211(237), Ser42(70)
amino acids in the sphere within 6 Å from the inhibitor.
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2-Carboxythiophene-5-boronic acid in the active site of BlaC and TEM-1

Figure 64: 2-Carboxythiophene-5-boronic acid in the active site of BlaC (top) and TEM-1
(bottom).
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Table 9: 2-Carboxythiophene-5-boronic acid in the active site of BlaC and TEM-1.
2-Carboxythiophene-5-boronic acid
3CG5(1ERO)
Ser42(70)
Lys45(73)
Ile75 (Tyr105)
Ser100(130)
Gly102 (Asn132)
Glu140(166)
Asn144(170)
Arg194 (Leu220)
Lys208(234)
Thr209 (Ser235)
Thr211 (Ala237)
Ala217 (Arg243)

BlaC

BlaC
TEM-1
Å
Side chain Oxygen to Boron
3.66
NH(H) to C(1)
3.93
N(H) to OH(O) H-b
2.40
NH(H) to C(4)
C’3 to C5
3.64
αCO(O) to OH(H) Hb
2.47
NH(H) to OH(O)
H-b
OH(O) to OH(H)
2.26
NH(H) to CO(O)
4.10
N(H) to C(3)
NH(H) to CO(O)
H-b
5.41
OH(H) to CO(O) H-b OH(H) to CO(O)
H-b
2.17
OH(H) to CO(O) H-b αNH(H) to S
2.19
NH(H) to NO(O) H-b NH(H) to CO(O)
H-b

TEM-1
Å
4.45
3.55
2.76
2.52
2.75
2.34
2.69
2.20

See page 82 (Table 8) for abbreviations.

Table 10: 2-carboxythiophen-5-boronic acid showing evidence of stacking.
2-Carboxythiophen-5-boronic acid in BlaC
[I]
Ki (M)
[Ez]
[I]/Ki
7.024E-03 4.925E-04
2.40E-05
14
2.489E-06 1.272E-06
1.20E-08
2
As the concentration of the inhibitor is lowered the Ki is lower. The lowest Ki that has been
obtained without compromising the ratio [I]/Ki that should be greater than 1 is 1.272 µM.
Txuzuki et al., (2002) have determined the interaction energies of parallel and perpendicular
thiophene dimer -1.71 and -3.12 kcal/mol respectively. Because of these interactions we may
expect that some molecules of the inhibitor will not compete for the active site at high
concentration.
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Figure 65: 2-Carboxythiophene-5-boronic acid in the active site of BlaC (3CG5). This
picture in DiscoveryStudio suggests strong interactions between Thr209(235) and Thr211(237)
and the carboxyl group of the thiophene. Also it suggests a strong interaction between the
boronate moiety and Ser42(70), LYs45(73), Ser100(130), and Glu140(166).
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Figure 66: 2-Carboxythiophene-5-boronic acid in the active site of TEM-1 (1ERO). This
picture in DiscoveryStudio shows strong interactions between the carboxyl group and Ser235,
and Arg243; the boronate moiety is in strong interaction with the carboxyl end oxygen of Ala237
(Oxyanion hole).
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2-Carboxythiophene-5-boronic acid in the active site of BlaC.

Figure 67: 2-Carboxythiophene-5-boronic acid in the active site of BlaC. Interactions
between enzyme and the carboxyl moiety of the ligand. Thr209, Arg194, Thr211.
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Figure 68: 2-Carboxythiophene-5-boronic acid in the active site of BlaC. Distances between
Ile75, Lys45, and Ly208 and the inhibitor.
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2-Carboxythiophene-5-boronic acid in the active site of TEM-1 (1ERO).

Figure 69: 2-Carboxythiophene-5-boronic acid in the active site of TEM-1 (1ERO). Surface
on within 10.0 Å of the inhibitor. A list of amino acids in the 10.0 Å sphere from the inhibitor is
shown in the window at the right.
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Figure 70: 2-Carboxythiophene-5-boronic acid in the active site of TEM-1.
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Figure 71: 2-Carboxythiophene-5-boronic acid in the active site of TEM-1. Interactions
between the carboxyl group of the inhibitor and the nearest side chains in the active site.
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Figure 72: 2-Carboxythiophene-5-boronic acid in the active site of TEM-1. Possible ring
stacking between the inhibitor and Tyr105.
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Figure 73: 2-Carboxythiophene-5-boronic acid in the active site of TEM-1. Ala237 and the
inhibitor.
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Figure 74: 2-Carboxythiophene-5-boronic acid in the active site of TEM-1.
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Figure 75: 2-Carboxythiophene-5-boronic acid in the active site of TEM-1. Lys73, Glu166,
Asn170, Lys73, and Leu220 seem to be too far from the ligand to have meaningful interactions.
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1,1,1- Trichloro-2,2-bis(4-chlorophenyl)ethane (4,4’-DDT) in the active site of BlaC (3CG5).

Figure 76: 4,4’-DDT in the active site of BlaC (3CG5).
Table 11: Important interactions for 4,4’-DDT in BlaC (3CG5) in the active site.

3CG5
Ile75
Thr211
Thr209
Ser42
Lys45
Ile75
Lys208

Å
2.09
2.64
2.77
3.50
3.73
3.80
5.25

Enzyme
Residue
γH
γH
γH
O
εNH(H)
H's
εNH(H)

Ligand
C'2H
mCl
mCl
C'4F
C'4Cl
Rings
C'3H

Hydrogen
bond
distance
yes
yes
yes
yes
yes

See page 82 (Table 8) for abbreviations.
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Figure 77: Residues Ile75, Lys208, Thr211 and Lys45 and DDT.
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Figure 78: Wireframe model on top and space filling model in the bottom of the active site
of BlaC (3CG5) with 4,4’-DDT.
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Figure 79: 4,4’-DDT in the active site of BlaC (3CG5). Surface on within 10.0 Å of the
inhibitor. A list of amino acids in the 10.0 Å sphere from the inhibitor is shown in the window at
the right. No coordinates were entered in AutoDock Vina for Ser42(70)-γO.
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Figure 80: Hydrogen bonds for 4,4’-DDT in the active site of BlaC (3CG5). Possible
hydrogen bonds between Thr209-γO and one of the methyl Chlorides in the small molecule. The
same is observed for of Thr211-γO and the ligand.
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Figure 81: 4,4’-DDT in BlaC (3CG5) Active Site ball and sticks (Sculpt). The model shows
Ser42(70)-γO opposite the trichloromethyl moiety of 4,4’-DDT.
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Figure 82: Study of boronic acids with fluoride substituents inhibiting BlaC (3CG5). The
pictures are in ascending order of Ki from kinetic experiments.

3,4,5-Trifluorophenylboronic acid
Ki, 175.7 µM

2,3,4,5-Tetrafluorophenylboronic acid
Ki, 228.6 µM
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Figure 82: Study of boronic acids with fluoride substituents inhibiting BlaC (3CG5). The
pictures are in ascending order of Ki from kinetic experiments (Continued).

3,5-Bis(trifluoromethyl)benzylboronic acid
Ki, 302.3 µM

2,3,5-Trifluorophenylboronic acid
Ki, 477.2 µM
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Figure 82: Study of boronic acids with fluoride substituents inhibiting BlaC (3CG5). The
pictures are in ascending order of Ki from kinetic experiments (Continued).

5-Trifluoromethyl-1,3-phenyldiboronic acid
Ki, 643.8 µM

3-Chloro-4-fluorobenzeneboronic acid
Ki, 657.6 µM
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Figure 82: Study of boronic acids with fluoride substituents inhibiting BlaC (3CG5). The
pictures are in ascending order of Ki from kinetic experiments (Continued).

3-Carboxy-4,5-difluorophenylboronic acid
Ki, 1,468.7 µM

2,3,4,6-Tetrafluorophenylboronic acid
Ki, 2,183.6 µM
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Figure 82: Study of boronic acids with fluoride substituents inhibiting BlaC (3CG5). The
pictures are in ascending order of Ki from kinetic experiments (Continued).

2,4,6-Trifluorophenylboronic acid
Ki, 5,998.6 µM
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Figure 83: Study of boronic acids with polyatomic substituents at a meta position in the
active site of BlaC (3CG5). The pictures are in ascending order of Ki from kinetic
experiments.

2-Carboxythiophene-5-boronic acid
Ki, 1.272 µM

3-Nitrophenylboronic acid
Ki, 213.9 µM
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Figure 83: Study of boronic acids with polyatomic substituents at a meta position in the
active site of BlaC (3CG5). The pictures are in ascending order of Ki from kinetic
experiments (Continued).

3,5-Bis(trifluoromethyl)benzeneboronic acid
Ki, 302.3 µM

5-Trifluoromethyl-1,3-phenyldiboronic acid
Ki, 643.8 µM
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Figure 83: Study of boronic acids with polyatomic substituents at a meta position in the
active site of BlaC (3CG5). The pictures are in ascending order of Ki from kinetic
experiments (Continued).

3-carboxy-5-nitrophenylboronic acid
Ki, 844.9 µM
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Figure 84: Study of structure activity relationship of boronic acids as inhibitors of Bacillus
cereus β-lactamase I.
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Figure 84: Study of structure activity relationship of boronic acids as inhibitors of Bacillus
cereus β-lactamase I (Continued).
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Figure 84: Study of structure activity relationship of boronic acids as inhibitors of Bacillus
cereus β-lactamase I (Continued).
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Figure 84: Study of structure activity relationship of boronic acids as inhibitors of Bacillus
cereus β-lactamase I (Continued).
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Discussion
As shown in tables 1, 2, and 3, there is no exact correlation between the Ki values obtained
experimentally and the Ki obtained in silico by AutoDock Vina. There is however, a correlation
in the sense that the Ki for a little more than half of the compounds fall in the micromolar range.
The major drawback for docking is that there is no function that recognizes boron as an electron
sink. In modeling, carbon was inserted instead of boron and was attached to two hydroxide
groups and a hydrogen. The γO of Ser42(70) would then seek the hydrogens from these
hydroxide groups for hydrogen bonding. The more hydrogen bonds we get the more likely this
molecule will show low Ki by in silico analysis. Hydrogen bonds are easier to identify, whereas
other types of interactions are less evident. Ile75 in BlaC (3CG5) and its counterpart Tyr(105) in
TEM-1 (1ERO) are two side chains that seem of importance in stabilizing the inhibitor molecule
in the active site via van der Waals interactions and ring stacking interactions respectively. What
is of importance here is the relative position not the lowest Ki. The attempt is to find a pattern
that would help us to predict the next best family of inhibitors. Introducing coordinates in the
docking program produced a lower Ki depending on how well the ligand fit in the active site
nevertheless the higher Ki should not be eliminated because the inhibitor can still work.
Therefore, scanning solely in in silico to eliminate the worst or accept only the best is a mistake.
Proof of the above is the case of 3,5-Bis(trifluoromethyl)benzeneboronic acid which showed a
high Ki in silico but it shows a good position in the compounds tested in BlaC. Moreover, in
BlaC the fluorinated aryl boronic acid are shown to tilt to the side of Ile75(105) as in a sigma pi
interaction, the 3,5-Bis(trifluoromethyl)benzeneboronic acid however, engage Ile75(105) on both
sides. The same happens with 5-trifluoromethyl-1,3-phenyldiboronic acid, 3-carboxy-5nitrophenylboronic acid. The same happens also with DDT which has two phenyl groups
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attached to trichloroethane moiety. In each of the aforementioned molecules two bulky groups sit
on each side of the prominence of Ile75(105). It has been observed that whenever there are three
bulky substituents including the boronate moiety two of them fall on each side of Ile75(105), the
inhibitor does not tilt to the side as in molecules where all substituents are single atoms. It has
been observed that when there are only two bulky substituents including the boronate moiety the
other group would orient itself toward Thr209(Ser235), Thr211(Ala237), Lys208(234) and away
from Ile75(105) and the aromatic ring may be in sigma pi stacking interaction with Ile75(105).
In the case of 4,4’-DDT the experimental Ki and the AutoDock Vina’s Ki are close,
experimental 48 µM and Vina’s 40 µM. For the DDT Vina’s docking was done without centering
the molecule in the active site, AutoDock Vina was allowed to choose another active site. As a
result a better Ki was obtained. The rationale for this is that the chlorines from the
trichloromethyl moiety of the 4,4’-DDT would not look for of Ser42(70)- γO because this
oxygen is deprotonated and would evade chlorine atoms. The model shows that the
tricholomethyl moiety is in fact far away from Ser42(70)- γO. The ligand is in the active site,
however. Most of the interactions are van der Waals weak interactions, Ile75 being a key player
since the two phenyl groups of 4,4’- DDT interact on each side of the Ile75 side chain. The
thiophenes seem to be of particular importance in BlaC as well as in TEM-1. In this case it
should be noticed that the compound second in effectiveness to 2-carboxy-5-thipheneboronic
acid is 3-carboxyphenylboronic acid. Both compounds have a carboxyl group on the meta
position to the boronate moiety. According to Beesley (1983) in studying class C β-lactamases,
the affinity falls in the order meta > para > ortho in boronic acid inhibitors for class C βlactamases. This may hold true for the class A β-lactamase enzymes and that the thiophenes may
have an advantage over the phenylboronic acid in that the angle is different between the boronate
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and the carboxyl group, it seems wider in the thiophene than in the phenylboronic acid. The key
for a better inhibitor may be in changing the angle between these two moieties but maintaining
their angles between 120˚ and 180˚. Thus we count with several elements for more exploration,
the boronate moiety remains unchanged, the thiophene, the carboxyl group meta to boronate,
leaving positions 3 and 4 of the thiophene free to experiment with. Hydrophobic are called for in
this two positions so that the solvent would drive the molecule inwards into the active site since
the driving force for boronic acid interaction with the serine enzymes is the hydrophobic effect
(Weston et al., 1998)
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Conclusions
1) Boronic acids are inhibitors of Mycobacterium tuberculosis β-lactamase (BlaC) and Bacillus
cereus 569/H9 β-lactamase I TEM-116.
2) The thiophene ring is needed because is aromatic, it can enter into sigma pi interactions with
Tyr105 in the TEMs enzymes and it shows that it may a better angle somehow wider than the
120˚ observed in 3-carboxyphenyl boronic acid.
2) 2-Carboxythiophen-5-boronic acid and possible its derivatives are of interest; 2carboxythiophen-5-boronic acid binds tightly to both enzymes studied in this research.
3) Two bulky groups at meta position to each other and to the boronate moiety bind in a way
that both sit at each side of Ile75 in BlaC.
4) Combining the features that a carboxyl group meta to the boronate moiety binds away from
Ile75 and that two bulky groups engulf Il75 would lead to a better inhibitor in BlaC.
6) 2-Carboxythiophene-5-boronic acid and 4,4’-DDT are the key for better inhibitors in BlaC.
7) 2-Carboxythiophen-5-boronic acid and 4,4’-DDT are also the key for better inhibitors of the
TEMs. In this case the thiophene group is in pi-pi stacking interaction with Tyr105 and the
usual carboxyl group and the boronate moiety look for their appropriate interactions Ser235
for the carboxyl group and the Ser70 for the boronate moiety. In silico experiments favored
the inhibition of TEM-1 (1ERO) with a Ki of 17 µM. Therefore the combinations of these
two molecules should also be considered for designing inhibitors of the TEMs.
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Appendix A
Interactions of clavulanate in the active site of BlaC as is in the crystal structure 3CG5
compared to results from AutoDock Vina non-hydrolyzed and hydrolyzed clavulanic acid.
ΔG for the non-hydrolyzed structure of clavulanic acid (Figure 69) produced by AutoDock Vina
is -6 kcal/mol which would translate to a Ki of 40 µM which is compatible with the ΔG Vina
returned for the boronic acid tested and DDT. Therefore Vina results should be trusted.

Figure 85: Interactions in the active site of BlaC (3CG5) and clavulanate as is in the crystal
structure from NCBI. No docking was performed therefore no ΔG from AutoDock Vina was
obtained.
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Figure 86: Interactions of clavulanate in the active site of BlaC (3CG5) before hydrolysis.
This was done by docking with AutoDock Vina. Vina’s ΔG = -6
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Figure 87: Interactions of clavulanate in the active site of BlaC (3CG5) after hydrolysis.
A carboxyl group was placed in position 7 of the oxapenam (clavam) (See figure 1) so that
Ser42(70)-γO would get attracted to this end of the molecule and not the hydroxyl in the
hydroxyethyledene moiety. Compare this figure with figure 68. Vina’s ΔG = -5.3
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Appendix B
Effect on docking when no coordinates are set for the active site in VcPpt AutoDock Vina.
The effect of not limiting the binding of the inhibitor to the active site is that the inhibitor binds
far from the active site.

Figure 88: Effect on ducking if no coordinates are set for the active site in VcPpt AutoDock
Vina. The picture shows 2,3,4,6-Tetrafluorurophenylboronic acid in TEM-1 (1ERO) which is
located more than 15 Å away from Ser70-γO.
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Appendix C
Programs used for modeling.

Figure 89: Programs used for modeling Sculpt, Swiss-PdbViewer, and DiscoveryStudio.
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Appendix D
Database created to account for all trials with boronic acids versus β-lactamase from
Bacillus cereus 569/H9

Figure 90: Access database from Microsoft was used in the analysis of boronic acids and
their Ki for SAR.
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Appendix E.

Figure 91: Color code used by DiscoveryStudio Visualizer program in the 2D
representation of the enzyme-ligand interactions.
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